Controlled substance prescribing trends and physician and pharmacy utilization patterns: Epidemiological analysis of the maine prescription monitoring program from 2006 to 2010

Journal of Substance Use

Volumn 18, Issue 6, 2013, Pages 467-475

  McCall III, Kenneth L ^a   Tu, Chunhao ^a   Lacroix, Matthew ^a   Holt, Christina ^b   Wallace, Kevin L ^a   Balk, Jonathan ^a  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

Controlled substance; Hypnotic; Narcotic; Opioid; Prescription; Prescription monitoring program; Stimulant

Indexed keywords

AMPHETAMINE; ANALGESIC AGENT; CENTRAL STIMULANT AGENT; CONTROLLED SUBSTANCE; ILLICIT DRUG; OXYCODONE; PRESCRIPTION DRUG;

ARTICLE; DATA BASE; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LAW ENFORCEMENT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHARMACY; PHYSICIAN; POPULATION DENSITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RETROSPECTIVE STUDY;

EID: 84887914027     PISSN: 14659891     EISSN: 14759942     Source Type: Journal    
DOI: 10.3109/14659891.2012.685794     Document Type: Article

References (24)

1. Agresti, A. (2002). Categorical data analysis. Hoboken, NJ: John Wiley& Sons, Inc.
2. Agresti, A., Bini, M., Bertaccini, B.,& Ryu, E. (2008). Simultaneous confidence intervals for comparing binomial parameters. Biometrics, 64(4), 1270-1275.
3. Buurma, H., Bouvy, M. L., De Smet, P. A., Floor-Schreudering, A., Leufkens, H. G.,& Egberts, A. C. (2008). Prevalence and determinants of pharmacy shopping behaviour. Journal of Clinical Pharmacy and Therapeutics, 33, 17-23.
4. Dahl, J. L.,& Gordon, D. B. (2002). Joint Commission pain standards: A progress report. APS Bulletin, 12, 6.
5. El-Aneed, A., Alagherbandan, R., Gladney, N., Collins, K., Macdonald, D.,& Fischer, B. (2009). Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. Journal of Substance Use, 14(2), 75-83.
6. Epidemic: Responding to America's Prescription Drug Abuse Crisis. (2011). Retrieved from http://www.whitehouse.gov/sites/default/files/ondcp/issues- content/prescription-drugs/rxabuseplan.pdf
7. Hall, A. J., Logan, J. E., Toblin, R. L., Kaplan, J. A., Kraner, J. C., Bixler, D.,& Paulozzi, L. J. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA, 300(22), 2613-2620.
8. Joranson, D. E.,& Gilson, A. M. (2005). Drug crime is a source of abused pain medications in the United States. Journal of Pain and Symptom Management, 30, 299-301.
9. Katz, N., Panas, L., Kim, M., Audet, A. D., Bilansky, A., Eadie, J.,& Carrow, G. (2010). Usefulness of prescription monitoring programs for surveillance: Analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol and Drug Safety, 19, 115-123.
10. Maine Office of Substance Abuse Community Epidemiology Surveillance Network. (2010). Substance abuse trends in maine. Retrieved from http://www.maine.gov/dhhs/osa/pubs/data/2010/CESNReport032010.pdf
11. Maine Prescription Monitoring Program. (2010). Information for prescribers. Retrieved from http://maine.gov/dhhs/osa/data/pmp/prescriber.htm
12. Paolozzi, L. J., Hones, C. M.,Mack, K. A.,& Rudd, R. A. (2011). Vital signs: Overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR, 60(43), 1487-1492.
13. Pastor, P. N.,& Reuben, C. A. (2008). Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. National Center for Health Statistics. Vital and Health Statistics, 10(237), 1-22.
14. Pradel, V., Frauger, E., Thirion, X., Ronfle, E., Lapierre, V., Masut, A., Micallef, J. (2009). Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol and Drug Safety, 18, 36-43.
15. R Development Core Team. (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Retrieved from http://www.R-project.org/.
16. SAS Institute Inc. (2008). Enhancements in SAS 9.2 Software. Cary, NC: SAS Institute Inc.
17. Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Retrieved from http://www.samhsa.gov/ data/2k9/2k9Resultsweb/web/2k9results.pdf
18. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2010). Treatment Episode Data Set (TEDS): 1998-2008. State admissions to substance abuse treatment services, DASIS Series: S-55, HHS Publication No. (SMA) 10-4613. Retrieved from http://www.samhsa.gov/data/DASIS/TEDS2k8Stnov04.pdf
19. US Census Bureau. United States Census (2010). Retrieved from http://2010.census.gov/2010census/index.php
20. US Department of Health and Human Services, National Institutes of Health. National Institute on Drug Abuse Research Report Series: Prescription Drugs Abuse and Addiction. (2005). Retrieved from http://www.nida.nih. gov/ResearchReports/Prescription/Prescription.html
21. US Department of Justice Drug Enforcement Administration Office of Diversion Control. (2011). Controlled substance schedules. Retrieved from http://www.deadiversion.usdoj.gov/schedules/orangebook/ccsalpha.pdf
22. Warner, M., Chen, L. H.,& Makuc, D. M. (2009). Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief, Sep:(22):1-8. Retrieved from http://www.cdc.gov/nchs/data/ databriefs/db22.htm.
23. White, A. G., Birnbaum, H. G., Schiller, M., Tang, J.,& Katz, N. P. (2009). Analytic models to identify patients at risk for prescription opioid abuse. American Journal of Managed Care, 15(12), 897-906.
24. Wilsey, B. L., Fishman, S.M., Gilson, A. M., Casamalhuapa, C., Baxi, H., Lin, T. C., Li, CS. (2011). An analysis of the number of multiple prescribers for opioids utilizing data from the California prescription monitoring program. Pharmacoepidemiol and Drug Safety, 20(12), 1262-1268.